Dana L. Schalk
Publications by Year
Research Areas
Prostate Cancer Treatment and Research, Hormonal and reproductive studies, CAR-T cell therapy research, Immunotherapy and Immune Responses, Cancer Immunotherapy and Biomarkers
Most-Cited Works
- → B cells from patients with multiple sclerosis induce cell death via apoptosis in neurons in vitro(2017)114 cited
- → Targeted delivery of siRNA to activated T cells via transferrin-polyethylenimine (Tf-PEI) as a potential therapy of asthma(2016)112 cited
- → Clinical and immune responses to anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (EGFR BATs) in pancreatic cancer patients(2020)59 cited
- → A Th1 cytokine–enriched microenvironment enhances tumor killing by activated T cells armed with bispecific antibodies and inhibits the development of myeloid-derived suppressor cells(2011)50 cited
- → CD20-Targeted T Cells after Stem Cell Transplantation for High Risk and Refractory Non-Hodgkin's Lymphoma(2013)39 cited
- → Preferential expression of functional IL-17R in glioma stem cells: potential role in self-renewal(2016)36 cited
- → Phase II clinical trial using anti-CD3 × anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) consolidation therapy for HER2 negative (0–2+) metastatic breast cancer(2021)34 cited
- → Microenvironment generated during EGFR targeted killing of pancreatic tumor cells by ATC inhibits myeloid-derived suppressor cells through COX2 and PGE2 dependent pathway(2013)33 cited
- → Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer(2022)29 cited
- → Targeting refractory/recurrent neuroblastoma and osteosarcoma with anti-CD3×anti-GD2 bispecific antibody armed T cells(2024)24 cited